

Dear Sir:

Responsive to the Office Action mailed July 12, 2006, Applicants make the following elections.

**REMARKS**

Claims 1-63 are pending. In response to the previous Office Action of March 23, 2006 the Applicants restricted the invention to Group I as follows:

Group I: Claims 1-24, 42-44, 63 drawn to nodulisporic acid compound and to spot on formulation comprising a nodulisporic acid derivative, carrier, and optionally a crystallization inhibitor, classified in class 514, subclass 410, class 548 subclass 417.

The Examiner graciously acknowledged Applicant's election of Group I, however in a Supplemental Restriction Requirement, the Examiner requested the election of a specifically disclosed composition and a specifically named or defined liquid carrier vehicle.

Therefore, Applicants respectively elect the following:

- a. Specific Nodulisporic Acid: t-butyl nodulisporamide.
- b. Specific Liquid Carrier: Transcutol


This election is made with traverse. Furthermore, it is explicitly stated that these amendments should not give rise to any estoppel, as they are not narrowing amendments.

If any fee or extension of time is required to obtain entry of this Response, the undersigned hereby petitions the Commissioner to grant any necessary time extension and authorizes charging Deposit Account No. 502354 for any such fee not submitted herewith.

The Examiner is invited to contact the undersigned at 678-638-3805, at the Examiner's convenience, to resolve any issues concerning this Response.

Respectfully submitted,

By:

A handwritten signature in black ink, consisting of a large, stylized 'J' followed by a horizontal line and a diagonal stroke.

Judy Jarecki-Black, Ph.D.,J.D.  
Reg. No. 44,170  
678-638-3805

Date: 09 AUG 06